Stevanato Group S.p.A. delivered robust revenue growth in 2025, driven by its integrated bio-pharma solutions and customer-centric manufacturing model. Despite facing material internal control weaknesses and product complexity challenges, the company is expanding capacity notably in Italy and the U.S. Its capital allocation reflects steady dividend payments and significant investment in production capabilities. Ongoing remediation efforts aim to strengthen reporting controls while its global footprint and specialized offerings create durable competitive barriers.